search
Back to results

Preoperative Alpha Blockade for Pheochromocytoma

Primary Purpose

Pheochromocytoma, Paraganglioma

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Phenoxybenzamine
Doxazosin
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pheochromocytoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults with pheochromocytoma / paraganglioma undergoing surgical resection

Exclusion Criteria:

  • Children < 18 years

Sites / Locations

  • University of California, Los angelesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Phenoxybenzamine

Doxazosin

Arm Description

3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).

3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).

Outcomes

Primary Outcome Measures

Hemodynamic instability
Arterial line blood pressure measurements will be extracted from the electronic medical record every 60 seconds. The area under the curve outside predefined blood pressure thresholds (systolic blood pressure > 160, < 80) will be summed to create a hemodynamic instability index. The hemodynamic instability index will be compared between phenoxybenzamine and doxazosin arms.

Secondary Outcome Measures

Mortality
Death within 30 days of surgery
Drug versus inpatient costs
The average wholesale price of the drug will be used in combination with the patient's cost per pill to estimate drug costs. Inpatient costs will be captured by charges after applying cost to charge ratios. Preoperative drug costs and inpatient costs will be compared between phenoxybenzamine and doxazosin arms.
Quality of life- physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role-limitations due to emotional problems, and mental health
Patients will take the SF-36 as well as a symptom survey describing the frequency and impact on their quality of life at several time points including prior to starting alpha blockade, immediately prior to surgery after being sufficiently blocked, and postoperatively at 30 days, 3 months, 6 months, and 1 year
Morbidity
Morbidity will be graded by Clavien Classification

Full Information

First Posted
May 31, 2017
Last Updated
September 18, 2019
Sponsor
University of California, Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT03176693
Brief Title
Preoperative Alpha Blockade for Pheochromocytoma
Official Title
Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Recruiting
Study Start Date
May 5, 2017 (Actual)
Primary Completion Date
May 2023 (Anticipated)
Study Completion Date
May 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pheochromocytoma is a rare, catecholamine (ex. adrenaline) secreting tumor that requires preoperative alpha blockade to minimize intraoperative hemodynamic instability, thereby reducing intra- and postoperative morbidity and mortality. Phenoxybenzamine is a non-selective alpha blocker that is significantly more expensive and is associated with increased adverse effects in comparison with selective alpha blockers such as doxazosin. Retrospective studies show minimal differences in hemodynamic instability and no differences in postoperative morbidity and mortality between selective vs. non-selective alpha blockers. This study is a randomized controlled trial that will compare hemodynamic instability, morbidity, mortality, cost, and quality of life between patients blocked with phenoxybenzamine vs. doxazosin.
Detailed Description
Pheochromocytoma is a catecholamine (ex. adrenaline) secreting tumor for which the primary treatment is surgical resection. Due to the hormones secreted by the tumor, alpha receptors on peripheral blood vessels are activated, causing constriction of these blood vessels and dangerously high blood pressure. During resection of the tumor, the source of excess hormone secretion is abruptly removed, which can lead to life-threatening blood pressure fluctuations during surgery. Alpha blockers are a class of medication that blocks the alpha receptor on blood vessels. Given preoperatively over a few weeks, these medications negate the effects of the excess hormones secreted by the pheochromocytoma, reducing the frequency and severity of dangerous blood pressure fluctuations intraoperatively and postoperatively. Preoperative alpha blockade is therefore critical to safely perform surgery to resect pheochromocytoma. Phenoxybenzamine, a non-selective alpha blocker, is the most common medication used to alpha block patients prior to pheochromocytoma resection. However, due to increasing drug costs and increased side effects in comparison with selective alpha blockers, there is a renewed interest in studying alternatives to phenoxybenzamine. Selective alpha blockers such as doxazosin are also commonly used to alpha block patients prior to pheochromocytoma resection. Selective alpha blockers are significantly less expensive and are associated with fewer side effects than phenoxybenzamine. Most retrospective studies comparing phenoxybenzamine with selective alpha blockers show no difference in intraoperative blood pressure fluctuations, morbidity, or mortality in pheochromocytoma resection. However, no prospective, randomized controlled trials comparing phenoxybenzamine to selective alpha blockers have been performed. The purpose of our study is to analyze preoperative, intraoperative, and postoperative outcomes in patients randomized to receive phenoxybenzamine (non-selective) or doxazosin (selective) for alpha blockade prior to pheochromocytoma resection. Outcomes will include postoperative morbidity and mortality, intraoperative hemodynamic instability, quality of life, and cost.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pheochromocytoma, Paraganglioma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Phenoxybenzamine
Arm Type
Active Comparator
Arm Description
3-4 weeks prior to date of surgery, patient will start phenoxybenzamine 10mg PO twice daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
Arm Title
Doxazosin
Arm Type
Experimental
Arm Description
3-4 weeks prior to date of surgery, patient will start doxazosin 1 mg PO daily. Phenoxybenzamine will then be titrated to a blood pressure <120/80 (sitting) with mild orthostatic hypotension (drop in systolic blood pressure by 20 points or diastolic blood pressure by 10 points from sitting to standing position); systolic blood pressure not less than 90 (standing).
Intervention Type
Drug
Intervention Name(s)
Phenoxybenzamine
Other Intervention Name(s)
Dibenzyline
Intervention Description
Non-selective alpha blocker
Intervention Type
Drug
Intervention Name(s)
Doxazosin
Other Intervention Name(s)
Cardura
Intervention Description
Selective alpha blocker
Primary Outcome Measure Information:
Title
Hemodynamic instability
Description
Arterial line blood pressure measurements will be extracted from the electronic medical record every 60 seconds. The area under the curve outside predefined blood pressure thresholds (systolic blood pressure > 160, < 80) will be summed to create a hemodynamic instability index. The hemodynamic instability index will be compared between phenoxybenzamine and doxazosin arms.
Time Frame
Intraoperative
Secondary Outcome Measure Information:
Title
Mortality
Description
Death within 30 days of surgery
Time Frame
30 days postoperatively
Title
Drug versus inpatient costs
Description
The average wholesale price of the drug will be used in combination with the patient's cost per pill to estimate drug costs. Inpatient costs will be captured by charges after applying cost to charge ratios. Preoperative drug costs and inpatient costs will be compared between phenoxybenzamine and doxazosin arms.
Time Frame
Preoperative (2-3 weeks prior to surgery) and inpatient (typical hospital stay < 1 week)
Title
Quality of life- physical functioning, role limitations due to physical problems, bodily pain, general health perceptions, vitality, social functioning, role-limitations due to emotional problems, and mental health
Description
Patients will take the SF-36 as well as a symptom survey describing the frequency and impact on their quality of life at several time points including prior to starting alpha blockade, immediately prior to surgery after being sufficiently blocked, and postoperatively at 30 days, 3 months, 6 months, and 1 year
Time Frame
From date of surgery (-2 to 3 weeks, -1 day, 30 days, 3 months, 6 months, 1 year)
Title
Morbidity
Description
Morbidity will be graded by Clavien Classification
Time Frame
Postoperatively during inpatient stay and during readmissions up to 30 days postoperatively

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults with pheochromocytoma / paraganglioma undergoing surgical resection Exclusion Criteria: Children < 18 years
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eric J Kuo, MD
Phone
310-206-0585
Email
ekuo@mednet.ucla.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Masha J Livhits, MD
Phone
310-206-0585
Email
mlivhits@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Yeh, MD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Los angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Masha J Livhits, MD
First Name & Middle Initial & Last Name & Degree
Eric J Kuo, MD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
25822781
Citation
Livingstone M, Duttchen K, Thompson J, Sunderani Z, Hawboldt G, Sarah Rose M, Pasieka J. Hemodynamic Stability During Pheochromocytoma Resection: Lessons Learned Over the Last Two Decades. Ann Surg Oncol. 2015 Dec;22(13):4175-80. doi: 10.1245/s10434-015-4519-y. Epub 2015 Mar 31.
Results Reference
background
PubMed Identifier
27552619
Citation
Kesselheim AS, Avorn J, Sarpatwari A. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform. JAMA. 2016 Aug 23-30;316(8):858-71. doi: 10.1001/jama.2016.11237.
Results Reference
background
PubMed Identifier
27561909
Citation
Randle RW, Balentine CJ, Pitt SC, Schneider DF, Sippel RS. Selective Versus Non-selective alpha-Blockade Prior to Laparoscopic Adrenalectomy for Pheochromocytoma. Ann Surg Oncol. 2017 Jan;24(1):244-250. doi: 10.1245/s10434-016-5514-7. Epub 2016 Aug 25.
Results Reference
result
PubMed Identifier
24939623
Citation
Kiernan CM, Du L, Chen X, Broome JT, Shi C, Peters MF, Solorzano CC. Predictors of hemodynamic instability during surgery for pheochromocytoma. Ann Surg Oncol. 2014 Nov;21(12):3865-71. doi: 10.1245/s10434-014-3847-7. Epub 2014 Jun 18.
Results Reference
result
PubMed Identifier
25456922
Citation
Brunaud L, Boutami M, Nguyen-Thi PL, Finnerty B, Germain A, Weryha G, Fahey TJ 3rd, Mirallie E, Bresler L, Zarnegar R. Both preoperative alpha and calcium channel blockade impact intraoperative hemodynamic stability similarly in the management of pheochromocytoma. Surgery. 2014 Dec;156(6):1410-7; discussion1417-8. doi: 10.1016/j.surg.2014.08.022. Epub 2014 Nov 11.
Results Reference
result
PubMed Identifier
20546874
Citation
Weingarten TN, Cata JP, O'Hara JF, Prybilla DJ, Pike TL, Thompson GB, Grant CS, Warner DO, Bravo E, Sprung J. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology. 2010 Aug;76(2):508.e6-11. doi: 10.1016/j.urology.2010.03.032. Epub 2010 May 23.
Results Reference
result
PubMed Identifier
12192533
Citation
Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002 Aug;26(8):1037-42. doi: 10.1007/s00268-002-6667-z. Epub 2002 Jun 19.
Results Reference
result

Learn more about this trial

Preoperative Alpha Blockade for Pheochromocytoma

We'll reach out to this number within 24 hrs